Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hyperinsulinemia
Interventions
Insulin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Type 1 Diabetes
Interventions
Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks, No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
Combination Product · Device
Lead sponsor
Ananda Basu, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Insulin Sensitivity, Apathy
Interventions
Diet without soy, Diet with soy
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
50 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed Not applicable Interventional Accepts healthy volunteers

Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)

NCT00694759
Conditions
Polycystic Ovary Syndrome
Interventions
pioglitazone, metformin, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Metabolic Disease
Interventions
Hyperglycemic Clamp, Kisspeptin-10, Placebo
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions
Tablets Intervention
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
45 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Recruiting Phase 1 Interventional Accepts healthy volunteers

Human Models of Selective Insulin Resistance: Alpelisib, Part I

NCT06354088
Conditions
Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
Interventions
Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus
Drug · Diagnostic Test · Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes, Hyperglycemia, Surgical Site Infection
Interventions
Tight Glycemic, Conventional Glycemic, Standard Glycemic
Drug
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Type 1 Diabetes
Interventions
Observational
Other
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 26 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed No phase listed Observational

TODAY2 Phase 2 Follow-up

NCT02310724
Conditions
Type 2 Diabetes
Interventions
TODAY cohort
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 10 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo and Insulin monotherapy via CL, Sitagliptin and insulin/novolog via CL
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
14 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Diabetes Mellitus, Type 1
Interventions
AT247, NovoLog, Fiasp
Drug
Lead sponsor
Arecor Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
21
States / cities
Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 12 more
Conditions
Diabetes
Interventions
Meal replacement
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
20 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Tustin, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Metformin Effect on Brain Function in Insulin Resistant Elderly People

NCT03733132
Conditions
Insulin Resistance, Obesity, Obesity, Abdominal
Interventions
Metformin Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Type 1 Diabetes
Interventions
Closed loop, Home glucose monitoring, Insulin pump, Continuous glucose monitor
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 2 more
Conditions
Postbariatric Hypoglycemia
Interventions
Mizagliflozin
Drug
Lead sponsor
Vogenx, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Conditions
Depression, Type 1 Diabetes
Interventions
Cognitive behavioral therapy for adherence and depression
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Gestational Diabetes Mellitus
Interventions
Oral glucose tolerance test
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Peripheral Arterial Disease (PAD) in Cancer Patients
Interventions
ABI/TBI, Questionnaires
Diagnostic Test · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
109
States / cities
Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more
Conditions
Healthy Volunteer
Interventions
Walking on a Treadmill, Sedendary Activities Only
Other
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 11 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
Drug · Other · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California